Physician profile
David T Dang
NPI 1316359581
$1,872.09
in general payments reported to CMS, 2019-2025
22 companies · $898 in 2025
The $898 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $156 · 2021: $37.64 · 2022: $135 · 2023: $125 · 2024: $271 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,294.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $659.52 | 2025 | Bimzelx |
| Aroa Biosurgery Incorporated | $215.39 | 2025 | |
| Teleflex LLC | $162.67 | 2024 | Urolift |
| Abbvie INC. | $138.89 | 2022-2024 | Ubrelvy |
| Edwards Lifesciences Corporation | $116.58 | 2019 | |
| Ethicon US, LLC | $112.94 | 2020 | |
| Lilly USA, LLC | $71.47 | 2023-2025 | Mounjaro, Zepbound |
| Eisai INC. | $53.85 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $41.06 | 2019-2022 | |
| Amgen INC. | $40.66 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $39.14 | 2019 | |
| Boston Scientific Corporation | $26.40 | 2021 | |
| Glaxosmithkline, LLC. | $25.21 | 2024 | Trelegy Ellipta |
| Acadia Pharmaceuticals INC | $24.18 | 2023 | Nuplazid |
| Dexcom, INC. | $21.38 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $20.46 | 2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $19.28 | 2022 | |
| Horizon Therapeutics Plc | $18.44 | 2023 | Krystexxa |
| Novo Nordisk INC | $18.39 | 2024 | Ozempic, Rybelsus |
| Sanofi Pasteur INC. | $17.99 | 2019 | |
| Astellas Pharma US INC | $17.09 | 2024 | Veozah |
| Philips North America LLC | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.